在遗传性血管患者中探索疾病特异性代谢物特征
Adine Kanepa1, Jingzhi Fan2,3, Dmitrijs Rots1,4
1Riga Stradiņš University, Riga, Latvia.
Frontiers in immunology
|May 10, 2024
概括
新的生物标志物,如异黄甲尼丁,囊和氧,显示出对诊断遗传性血管 (HAE) 的前途. 这项研究有助于区分HAE与异常性血管 (AE),改善患者的护理.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 遗传性血管 (HAE) 是一种罕见的,危及生命的遗传性疾病,与C1酶抑制剂 (C1-INH) 缺乏有关.
- 经常出现的发作是HAE的特征,需要准确的诊断方法.
- 区分HAE与异常性血管 (AE) 对于适当的管理至关重要.
研究的目的:
- 为了探索HAE患者的代谢概况.
- 为了确定HAE.新型诊断生物标志物.
- 使用代谢特征来区分HAE与异常AE.
主要方法:
- 使用LC-MS对HAE患者,异常AE患者和健康对照组的血样本进行了有针对性的代谢分析.
- 统计分析包括T测试和折叠变化计算,以确定显著的代谢物差异.
- 接收器操作特征 (ROC) 分析,以评估已识别的代谢物的诊断潜力.
主要成果:
- 与对照组相比,HAE患者的异甲基尼丁,囊和基素显著改变.
- 酸有效地区分了HAE和异常AE.
- 一个特定的代谢物比率 (基 * 囊) / 肌氨酸 * 异甲氨酸) 作为HAE的诊断签名.
结论:
- 鉴定出异甲基尼丁,氨酸和氨酸是HAE诊断的潜在生物标志物.
- 新的生物标志物可以提高HAE诊断的准确性,及时性和成本效益.
- 这些发现支持为改善HAE患者护理量身定制的治疗选择.
相关概念视频
Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


